Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor Cell DNA (via Lutetium-177 Conjugated Peptide) (N/A)
- Target
- N/A
- Molecular classification
- DNA, Radiopharmaceutical, Peptide Conjugate
01
Overview
Lutetium-177 (^177Lu) conjugated peptides target tumor cells by binding to overexpressed receptors. Upon internalization, ^177Lu emits beta particles, causing DNA damage and cell death. Selectivity is achieved through peptide affinity for specific tumor-associated receptors. Gamma co-emission enables imaging for theranostic applications.
- Other names
- Lutetium-177 Peptide RadiotherapyLu-177 Peptide Therapy^177Lu-Targeted Radiotherapy
02
Mechanism of action
Beta particle emission causing double-stranded DNA breaks and cell death in targeted tumor cells.
03
Biological functions
Cell death inductionDNA damageTargeted radiotherapy
04
Disease associations
Cancer
05
Safety considerations
Myelosuppression (cytopenias)NephrotoxicityFatigueOff-target radiation exposureRisk of secondary malignancies
06
Interacting drugs
EB-PSMA-617
4 more in the full profile.
07
Biomarkers
PSMA expression (for prostate cancer)Somatostatin receptor expression (for neuroendocrine tumors)PD-L1 expression (for triple-negative breast cancer)CXCR4 expression (for neuroendocrine prostate carcinoma)Tumor uptake of radioligand (measured by imaging)
Beyond the preview
Go deeper on Tumor Cell DNA (via Lutetium-177 Conjugated Peptide) (N/A).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tumor Cell DNA (via Lutetium-177 Conjugated Peptide) (N/A).